ClinicalTrials.gg
RecruitingNCT04375306RFR-CABGUpdated Feb 1, 2024

Resting Full-cycle Flow Ratio (RFR) Versus Angiography to Guide Revascularization Strategy in Patients Undergoing Coronary Artery By-pass Grafting (CABG)

An interventional study of RFR guided CABG and Angio guided CABG in Coronary Artery Disease, sponsored by Diagram B.V.. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Diagram B.V. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Coronary Artery Disease with a site in Belgium — 26 open to participants now, 41 under way, 7 of them phase 3. Coronary Artery Disease · Belgium.

Planned enrollment
57th of 148
500 · median 282
Started
2020
with 10 others
No phase
79 of 189
11 open now
Primary completion
2024-10
later than 9 of 40 live
Registered
137th of 189
by date

Among the 189 studies in Coronary Artery Disease with a site in Belgium, this one is the 57th largest by planned enrollment of the 148 interventional ones that give a count, is one of 11 that started in 2020, is one of 79 with no phase, reaches primary completion later than 9 of the 40 other live ones, and was the 137th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

26 of the 189 studies in Coronary Artery Disease with a site in Belgium are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Coronary Artery Disease with a site in Belgium, or all of them as a file.
02

Study summary

Different trials have shown that fractional flow reserve (FFR) could successfully guide revascularization in patients undergoing percutaneous coronary intervention (PCI).

It is conceivable that a similar revascularization guidance could be useful also for surgical revascularization i.e. coronary by-pass graft (CABG). Experience learns that grafts placed on vessels with hemodynamically non-significant stenosis often occlude due to competitive antegrade flow.

Resting full-cycle Flow Ratio (RFR) is a measurement performed to evaluate the hemodynamic severity of coronary stenosis. Differently from FFR which is a measurement performed in maximal hyperemia, the RFR is a measurement that is performed in rest and therefore may predict better than FFR the baseline equilibriums that could lead to graft failure, while it has similar capacity to identify hemodynamically significant stenosis as FFR. It is unknown whether RFR guided CABG revascularization is superior as compared to angiography alone.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • RFR guided CABG
  • angiography guided CABG
  • Graft dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients between 18 or older undergoing CABG
  • Patients willing and capable to provide written

Exclusion criteria

Exclusion Criteria:

  • Previous CABG
  • Concomitant severe valvular disease intervention
  • Remaining (expected) coronary stenosis of > 50% diameter stenosis distally to graft anastomosis
  • \<30%
  • Known transmural myocardial infarction
  • Documented microvascular disease
  • RFR/FFR measurement judged impossible
  • \<2 years
  • Participation in other clinical trials
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    angiography guided CABG

    angiography guided CABG

    Procedure: Angio guided CABG

  • Experimental
    RFR guided CABG

    RFR guided CABG

    Procedure: RFR guided CABG

Interventions

  • ProcedureRFR guided CABG

    All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.

  • ProcedureAngio guided CABG

    All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.

06

What researchers measure

Primary outcomes

  1. Number of participants who deceased, had a Myocardial Infarction (MI), Clinically-Driven Target Vessel Revascularization (CD-TVR), Stroke or Graft Dysfunction at 3 months post CABG

    Time frame: 3 months

Secondary outcomes

  1. Cut-off value for the RFR that best predicts graft occlusion

    Time frame: Baseline

  2. Number of participants with graft dysfunction at 3 months post CABG

    Time frame: 3 months

  3. Major adverse cardiac or cerebrovascular event (MACCE), a composite of Death, MI, CD-TVR and Stroke at 1 year

    Time frame: 1 year

  4. Major adverse cardiac or cerebrovascular event (MACCE), a composite of Death, MI, CD-TVR and Stroke at 3 years

    Time frame: 3 years

  5. CD-TVR at 3 months post CABG

    Time frame: 1 year

  6. CD-TVR at 1 year post CABG

    Time frame: 1 year

  7. CD-TVR at 3 years post CABG

    Time frame: 3 years

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This has not been decided yet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Oct 2024, 56 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 56 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2020
First posted
May 5, 2020
StartActual
Feb 3, 2020
Primary completionEst.
Oct 31, 2024
CompletionEst.
Jun 30, 2027
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04375306
Lead sponsor
Diagram B.V.
Responsible party
Sponsor
First posted
May 5, 2020
Start date
Feb 3, 2020
Primary completion
Oct 31, 2024 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 1, 2024

Study contacts

Prof. E. Kedhi, MD, PhD
Contact
ekedhi@me.com
+31 384262999
S. Postma, PhD
Contact
rfrcabg.trial@diagram-zwolle.nl
+31 384262999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion